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Retrospectively, we analyzed the use of blood products in the Oncology Clinic of the 
Clinical Centre Nis in the period November 1
st 2007-November 1
st 2008, and also the 
influence of the treatment on degree of anemia and thrombocytopenia and use of blood 
products. None of the patients received the whole blood. In this period, 324 patients 
received the transfusion of blood components, 302 patients received 983 units of red cells 
(red blood cell concentrate, resuspended, washed, filtered), 17 patients received 5050 ml 
of platelets (single-donor concentrate or pooled platelet concentrate) and 5 patients 2200 
ml of fresh frozen plasma. An average use of red cell transfusion is 3,26 units, platelet 
concentrate 5,54, fresh frozen plasma 2 units per oncological patient who receives 
transfusion. The use of red cell units and platelet concentrate transfusion was adequate 
(91,85% of patients received transfusion of red cells when Hgb<70g/l, 89,2% of patients 
received platelet concentrate transfusion when platelet count was less than 20 x10
9/l). 
During radio and chemotherapy we noticed a decrease of hematological parameters' 
values, whereas the experimental group of patients were dependent on blood product 
transfusion. Statistically, a significant decrease of hemoglobin level and platelet count was 
observed in the patients treated only with radiotherapy who are the greatest consumers of 
blood products. Acta Medica Medianae 2008;47(4):13-18. 
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Introduction 
 
Blood and blood component therapy 
represent the application of cell and plasmatic 
blood components in order to correct anemia, 
thrombocytopenia and stop bleeding. The aim of 
chemotherapy is to reconstitute and maintain 
homeostasis in circulation of the blood using specific 
chemoproducts, thus influencing the volume of 
circulating blood and capacity for binding and 
transportation of the oxygen, chemostatic function 
of blood and activity of the mediator of immune 
response (1). By allogen transfusion, in the circulation 
of the recipient  different cells are introduced, of 
which mononucleus cells - T and B lymphocytes, 
dendrite cells, chematopoesis and other cells can 
survive longer and are able to be functional in 
circulation. Interaction of some of the mononuclear 
cells with immune system of the receiver and 
clinical consequences of those reactions depend 
on the degree of histocompatibility between donor 
and recipient, the period of time and way of 
storing blood, number and type of mononuclear 
cells, as well as the condition of patient's immune 
system (2,3). 
For years, transfusion of blood and blood 
products has been very important in supportive 
medical treatment of oncological patients. In that 
way, we have significantly reduced the mortality 
of patients with malignant diseases and decreased 
unwanted chemobiological disturbances occuring 
because of radio- and chemotherapy (4,5).   
In spite of a positive therapy effect, transfu-
sion can be joined with numerous unwanted effects, 
the reason of which the use of  transfusion is not 
without risks for patients (2). Therefore, before 
making a decision whether the patients should 
receive transfusion or not, it is very important to 
estimate all the damages and benefits. In the 
contemporary therapy, we use direct chemo-
therapy, the so-called selective transfusion which 
means selection of the specific component of 
blood that is the most suitable for correction of 
present deficit in patient, which reduces the risk 
of potential complications to minimal. By direct 
chemotherapy, a patient receives just the part of 
blood which he needs and there is no danger of 
overloading the blood circulation; sensibilisation 
to antigens of blood cells and plasma proteins is 
avoided, and transfusions are shorter and do not 
confine the patients to bed for a long period of 
time (3). Use of blood products in oncological patients treated with radio and chemotherapy             Ana Antić et al. 
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Oncological patients are the patients who 
experience transfusion treatment with difficulties 
(5). Most of the patients belong to the group of 
polytransfunded patients bearing the greater risk 
of post-transfusion reactions, and some of them 
are sensibilised to received blood-group antigens, 
which leads  to problems in finding out compa-
tible blood units. In some of the patients there 
occur disturbances of the immune system in the 
sense of the appearance of autoantibodies, 
paraproteins and forming ruloux formation red 
cells, which leads to difficulties in laboratory 
analyses during determining blood groups and 
compatibility tests (3,4). 
 
Aims 
 
The aim of this work was: 
− to establish an average use of blood components 
by malignant patients (number of red cells units, 
number of thrombocyte doses and number of 
units of fresh frozen plasma), 
− to determine the level of hemoglobin and 
number of platelets which represented the 
indications for transfusion, 
− to estimate the influence of the type of therapy 
on the levels of anemia and thrombocytopenia, 
as well as the difference in consumption of blood 
in comparison with other therapies, 
− to define the number and the type of complications 
occurring because of receiving transfusion. 
 
Material and methods 
 
Retrospectively, we analyzed the use of 
blood products in the Oncology Clinic of the 
Clinical Centre Nis in the period November 1
st 
2007-November 1
st 2008. Patients who received 
transfusion were treated at the Clinic or in the 
Daily Hospital Centre. Patients received: red cells 
resuspended in additive solution (SAGM), red cell 
resuspended in SAGM reduced in leucocytes and 
trombocytes, deplasmated red cells, deplasmated 
red cells reduced in leucocytes and trombocytes, 
washed red cells, filtered red cells, single-donor 
concentrate of platelets, pooled platelet concentra-
tes and fresh frozen plasma.  
Patients who received blood components 
were divided into three groups, according to the 
therapy treatment: 
I.  Patients treated only with radiotherapy 
II.  Patients treated only with chemotherapy 
III.  Patients treated with radio and chemotherapy. 
Control group comprised 200 patients who 
did not receive blood components in therapy. 
We used ABO and Rh(D) reagents Seraclone 
anti-A, anti-B and anti-D(RH1)332 (Biotest, 
Germany) for determination of blood groups in 
tubes, own-produced phenotyped screening red 
cells for antibody screening in tubes and red cells 
DiaMed, ID-DiaCell I, II for gel-filtration method 
of antibody screening (DiaMed, Switzerland), panel 
of red cells DiaMed, ID-DiaPanel for antibody 
identification using gel filtration method (DiaMed, 
Switzerland) and Seraclone Anti Human-Globulin 
monoclonal anti-IgG, anti-C3c, anti-C3d d for 
Coombs AHG test (Biotest, Germany). 
We determined a count of platelets, 
leucocytes and hemoglobin level at the beginning 
and during the therapy. 
Post-ransfusion reactions were recorded in 
a special form; one copy  with fulfilled results 
was returned to the Oncology Clinic, the other 
one remained in the Protocol in BTI. 
Obtained data were statistically processed 
using following the following tests: Shapiro-Wilk, 
χ
2 , t-test, ANOVA test and Tukey post hoc test. 
 
Results 
 
In the period of investigation, 324 patients 
received the transfusion of different blood 
components. Average age of patients was 
54,77±9,95 years. The youngest patient was 28, 
the oldest one was 83 years old. The analysis of 
the presence of malignant diseases in this 
investigation showed that the most frequent 
diagnosis was Ca mammae and  Ca cervicis uteri 
for women, and Ca pulmonum and Ca prostatae 
for men, which is in accordance with the data 
published by the World Health Organization.   
Distribution of blood groups of patients 
showed that the most frequent blood group was 
O Rh(D) positive, then A Rh(D) positive. This 
distribution is shown in Table 1. 
 
Table 1. Distrubution of blood groups of patients who received 
transfusion of blood products in the period of examination 
 
Blood group 
Number of 
patients 
Percentage 
(%) 
A+ 94  29% 
A- 13  4% 
O+ 116  36% 
O- 19  6% 
B+ 45  14% 
B- 6  2% 
AB+ 19  6% 
AB- 10  3% 
Total 324  100% 
 
Use of blood components (red cells, 
platelets, fresh frozen plasma) during the period 
of investigation is shown in Table 2. 
 
Table 2. Use of blood components (red cells, platelets, 
FFP) in period of investigation 
 
Blood component 
Number od 
doses/units 
Number of 
patients 
Red cells (resusp.i 
depl) 
920  
Red cells 
(washed,filtered) 
63  
302 
Platelets 
18 
pul.(5050m) 
17 
FFP 2200ml  5 Acta Medica Medianae 2008,Vol.47                     Use of blood products in oncological patients treated with radio and chemotherapy 
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An average use of red cells (red blood cell 
concentrate, resuspended, washed, filtered) is 
3,26 units per oncological patient who received 
transfusion, range from 1 to 9 units. Patients 
received 983 units, which is 4,87% of total units  
in that period in the Blood Transfusion Institute 
Nis (20514 units). 
An average use of platelet concentrates is 
5,94 single-donor concentrates or approximately 
one pooled platelet concentrate (it consists of 6 
single-donor concentrates) per oncological 
patient who received transfusion, range was   
from 4 to 12 concentrates. Out of 17 patients 
who received platelet concentrations, nine of 
them had hemorrhagic syndrome. 
An average use of fresh frozen plasma 
(FFP) was 440 ml- 2 units per oncological patient 
who received transfusion, range was  from 220 
ml to 1000 ml (1-5 units). Out of five patients 
who received FFP, four of them had a disturbance 
of coagulation system. 
We checked hemoglobin concentration (g/l) 
which was the indication for red cell transfusion, 
and platelet count (x10
9 /l) which was the 
indication for transfusion of platelets. 91,85% of 
patients received transfusion of red cells when 
Hgb was less then 70 g/l, 23,6% of patients had 
difficult form of anemia (Hgb<50g/l). 
Hemoglobine concentration as an indication for 
transfusion of red cells is shown on Graph 1. 
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Graph 1. Concentration of hemoglobin (g/l) in patients 
as indication for red cells transfusion 
 
Analysing the patients divided according to 
the type of therapy, we noticed a decrease of 
hemoglobin concentration after therapy, which 
was 19,83 g/l (z=4,18 and p>0,001). If we 
analyse each group, this value is different: 
• Group I- 24,81g/l (z=3,09, p<0,01) 
• Group II -17,82g/l (z=1,60, p>0,05) 
• Group III- 11,23g/l (z=3,20, p<0,01). 
In control group, hemoglobin concentration 
after therapy was by 10,73 g/l l less than the initial 
value (z=3,78, p<0,001), which was statistically 
significant decrease. The analysis of the obtained 
results showed that decrease of hemoglobin 
concentration was statistically significantly higher 
in experimental group than in the control one (t-
test=2,61, p<0,01), and also, that decrease of 
hemoglobin concentration was higher in the group I 
than in groups II and III (ANOVA and Tukey post 
hoc test, p<0,05). 
Patients from all the groups received different 
types of red cells in order to correct anemia, but 
the number of units the patients received differed 
between them. Total of 302 patients received red 
cells transfusion: 151 patient from group I, 32 
from group II and 119 patients from group III. 
Use of red cell components according to therapy 
type is shown in Table 3. 
 
Tab.3. Use of red cell units according to type of 
applicated therapy in experimental group 
 
Statistical 
parameter  Group I  Group II  Group III 
Xsr 3,54  1,36  1,17 
SD 1,40  0,57  0,72 
Xmin 1  1  1 
Xmax 7  3  4 
 
Group I - patients received radiotherapy 
Group II - patients received chemotheraphy 
GroupIII - patients received radio and chemotheraphy 
 
An average use of red cell transfusion was 
2,04±1,32 units, the least in group III, and the 
most in group I. ANOVA and Tukey post hoc test 
showed that the number of units the patients 
received treated only by radiotherapy was statistically 
larger than in other groups of patients, and also 
that difference between group I and II was not 
statistically significant. 
89,2% of patients received transfusion of 
platelets when the platelet count was less than 
20 x10
9 /l; 56,8% of patients had difficult form of 
thrombocytopenia (<10x10
9/l). Platelet count as 
an indication for transfusion of platelets is shown 
on Graph 2. 
 
Graph 2. Platelet number as indication for transfusion 
of platelet concentrates 
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An average platelet count in patients in 
experimental group was lower by 78,80 after the 
tretament (z=4,83, p<0,001), and differed 
according to the type of therapy: 
• Group I - 84,60 (z=3,38, p<0,01) 
• Group II -98,72 (z=1,90, p>0,05) 
• Group III- 51,24 (z=3,02, p<0,01). 
*Use of blood products in oncological patients treated with radio and chemotherapy             Ana Antić et al. 
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In control group, platelet account after the 
therapy decreased approximately by 19,75x10
9/l 
(z=3,62, p<0,001), which was statistically signifi-
cant decrease.  
Decrease of platelet account is statistically 
significant greater in experimental group then in 
control one (t-test=3, 78, p<0,001). 
In order to correct the platelet count we 
used transfusion of  platelet concentrates (single-
donor or pooled concentrate, which consists of 
six single-donor concentrates). Out of 17 patients 
who received platelet concentrates, seven 
patients were from group I, eight from group II 
and two patients from group III. The analysis of  
using platelet concentrates showed that patients 
in group II received statistically significantly 
more concentrates than patients from groups I 
and III. Use of platelet concentrates according to 
therapy type is shown on Chart 4. 
 
Table 4. Use of platelets according to type of therapy in 
experimental group 
 
Statistical 
parameter  Group I  Group II  Group III 
Xsr 6,10  7,18 3,04 
SD 2,38  4,11  1,21 
Xmin 3  4  3 
Xmax 6  12  6 
Group I - patients received radiotherapy 
Group II - patients received chemiotheraphy 
GroupIII - patients received radio and chemiotheraphy 
 
Transfusion can be joined with numerous 
unwanted effects, especially in polytransfunded 
patients. In the period of investigation, two transfu-
sion reactions were registered. After analyzing 
the pre-transfusion sample and post-transfusion 
sample of patients, and samples of the units 
patients received, we concluded there were not 
any immunohematological disagreements. We 
supposed that it was febrile non-hemolytic transfusion 
reaction in both cases. In the further treatment, 
the patients received leukoreduced red cells 
components (washed, filtered). 
Red blood cell antibodies were identified in 
four patients, one of them had positive DAT. That 
patient had auto antibodies in his serum.   
Identification of antibodies in sera of other 
patients showed different specificity: anti-Kell, 
anti-D and anti C+D. 
 
Discussion 
 
Even in the 21st century, malignant diseases 
still remain the great enigma. They show constant 
and apparent trend of increasing, influencing thus 
population mortality (5). The frequency of occurre-
nce of some of malignant diseases is in conformity 
with the data of the World Health Organization 
(in women, firstly, breast carcinoma, in men, 
lung carcinoma). 
The results of this investigation showed 
that the principle of the component transfusion 
therapy was fully obeyed, because none of the 
patients received whole blood (whole blood is not 
used in the Blood Transfusion Institute Nis; all of 
the units of fresh blood are separated during six 
hours from taking the blood). 
Malignant patients usually have normocite-
normochrom anemia (6). Sera iron and total 
capacity of binding iron are usually low, and sera 
feritin is high, pointing to blockade in transfer of 
iron from depo in progenitors of erythrocytes 
(6,7,8). In s ome patients we not iced anemia of  
higher degree because of blood loss, infiltration 
of bone marrow malignant cells or the effects of 
some additional factor (9,10). In the treatment of 
anemia in our oncological patients, we prepared 
red cell preparations: red cells resuspended in 
SAGM, red cell resuspended in SAGM reduced in 
leucocytes and trombocytes, deplasmated red 
cells, deplasmated red cells reduced in leucocytes 
and trombocytes, washed red cells, filtered red 
cells. The indication for transfusion of red cells 
was adequate in 91,85% of the patients as they 
received transfusion of red cells with Hgb<70 g/l. 
In elderly patients suffering from cardiore-
spiratory diseases, transfusion was administered 
with Hgb<85 g/l, which is in line with the 
attitudes ofs Balint’s (11) and Turek attitude. The 
patients who received transfusion of deleucocyte 
red cells, had shorter hematological recovery, 
lower rate of infections and longer period without 
relapse of disease. Generally, each unit of red 
cells, transfunded to average adult person, can 
lead to growth of haematocrit by 0,03 and at the 
same time increasing the concentration of 
hemoglobin by 10 g/l, approximately (1,2). 
For curing thrombocytopenia, we use transfu-
sion of platelet concentrates, the indication for 
which was also adequate (89,2% transfusion of 
platelets were received by patients with the 
number of platelets less then 20x10
9/l). There 
are different attitudes concerning the application 
of platelet transfusion in reference to when the 
therapy should be implicated with review to 
degree of thrombocytopenia. Almost all  clinicians 
agree that platelet transfusions bear high risk of 
bacterial infection occurrence (trombocyte 
concentrates are stored at 22±2ºC) and alloimu-
nisation (12,13). Therefore, the number of 
transfusions of platelet concentrates should be 
reduced, that is, we should direct them  to the 
application of platelets from separator from one 
single donor with lower contents of leukocytes, 
which reduces the risk of alloimunisation of 
patients, with the prevention of transmission of 
intracellular pathogens such as CMV, HTLV-1 as 
well as the cause of the new variant Creutzfeldt-
Jacobs disease. With this type of platelets, it is  
possible to achieve the amount of about 2-4x10
11 
platelets per unit of concentrate (1,3). 
Transfusions of platelets should be limited also 
for the occurrence of refractoriness to platelets 
which appear in 10-15% patients who received 
large number of platelet transfusions (14,15). Acta Medica Medianae 2008,Vol.47                     Use of blood products in oncological patients treated with radio and chemotherapy 
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There is a common attitude that transfusions of 
platelet concentrates should be given when the 
number of platelets is 10x10
9/l if the patient has 
no sepsis or coagulopathy, and for invasive 
processes it is necessary to achieve the number 
of platelets up to 50x10
9/l (15,16). 
The use of fresh frozen plasma (FFP) was 
reduced to a minimum in five patients, which 
confirms the fact that FFP is no longer used as a 
replacement for albumin in order to correct 
hypoproteinemia. Indications for its use are very 
strict: congenital or acquired coagulopathy, overdo-
sed therapy with oral anticoagulants, massive 
transfusion with haemostatic deficit, trombotic 
thrombocytopenic purpura and hard liver 
diseases with active bleeding (17). 
Unwanted effects of transfusion therapy 
have been followed in the Haemovigilance system 
since 1997. Two registered posttransfusion reactions 
in oncological patients in the period of monitoring 
represent 15,85% of all reported reactions in the 
Blood transfusion Institute Nis in the research 
period. 
The percent of alloimunised patients is less 
than 1% (0,6%), which is in line with data  from 
literature (1,2); also, the highest frequency of 
antibodies is from Rh and Kell systems.  
The results of examination of patients that 
underwent the treatment by radio and chemo-
therapy show that there is a significant decrease 
of hemoglobin volume after the use of therapy in 
experimental rather than control group, signifi-
cantly greater in the group of patients treated 
only by radiotherapy. All the patients from this 
group received red cells, so the consumption of 
blood units was statistically greater in that group 
than in other groups. Other authors report that 
average level of hemoglobin concentration is lower 
by 46 g/l 30 days after chemotherapy (18,19). 
Reduction in the number of platelets was 
registered in all groups, but it was statistically 
higher in experimental group compared to control 
one. The greatest consumption of concentrated 
platelets was shown by the patients from the 
group treated only by radiotherapy. Average 
number of platelets after the application of 
therapy shows a decrease by 78,30x10
9/l. Having 
compared the obtained results with the results of 
other authors on the changes in the number of 
trombocytes after the use of chemotherapy, we 
could conclude that the average number of 
trombocytes was lower by 35x10
9/l in the 
examined group (19). 
Specificity of the patients with malignant 
diseases and necessity of long and frequent 
transfusion therapy in these patients requires the 
introduction of preventive measures in blood 
transfusion therapy (20,21). That is, first of all, 
reduction of the application of blood transfusion 
(patients frequently adapt to lower values of 
hemoglobin, so there is no need to insist on 
complete correction of parameters of erythrocyte 
group to normal values). During treatments  with 
radio and chemotherapy, patients need blood 
transfusion of different products, so it is 
necessary to provide for the patients only the 
deficient components. (22). In polystransfunded 
patients, transfusion of deleukocyted (filtered) 
erythrocytes is necessary (23). In order to 
correct the number of trombocytes, the use of 
platelets obtained on separator of blood cells is 
suggested (20). 
During transfusion, it is necessary to follow 
up the patients all the time, and to look for 
clinical, hematological and serological signs of 
posttransfusion reaction (24). 
 
Conclusion 
 
The principle of component transfusion therapy 
was completely obeyed in all the patients. None 
of the patients received the whole blood. An 
average use of red cell transfusion was 3,26 units, 
platelet concentrate 5,54, fresh frozen plasma 2 
units per oncological patient who received transfusion. 
During radio and chemotherapy we noticed a 
decrease of hematological parameters' values, 
whereas the experimental group of patients were 
dependent on blood product transfusion. Statistically, 
a significant decrease of hemoglobin level and 
platelet count was observed in the patients treated 
only with radiotherapy;therefore, these patients 
are the greatest consumers of blood products. 
In order to conduct an efficient transfusion 
management in the patients with malignant 
diseases, we have tobe up-to-date with the   
latest knowledge and attitudes about clinical use 
of blood products. 
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PRIMENA PRODUKATA OD KRVI KOD ONKOLOŠKIH BOLESNIKA 
LEČENIH RADIO I HEMIOTERAPIJOM 
 
Ana Antić 
1, Slađana Filipović 
2, Ivica Pejčić 
2 i Svetislav Vrbić 
2 
 
 
Retrospektivnom analizom procenjena je primena transfuzija na Klinici za onkologiju 
Kliničkog centra u Nišu u periodu 01.11.2007 - 01.11.2008. godine, kao i uticaj vrste 
terapije na stepen anemije i trombocitopenije, odnosno potrošnju produkata od krvi. Kod 
svih bolesnika obolelih od malignih bolesti ispoštovan je princip komponentne transfuzijske 
terapije. U praćenom periodu, 324 bolesnika primilo je krvne komponente, i to 302 
bolesnika 983 jedinice eritrocita (deplazmatisani, resuspendovani, isprani, filtrirani), 17 je 
primilo 5050 ml  trombocita (koncentrati, pul trombociti) i 5 bolesnika 2200 ml zamrznute 
sveže plazme (ZSP). Prosečna potrošnja eritrocita po onkološkom bolesniku koji prima 
transfuziju iznosi 3,26 jedinica, trombocita 5,94 doza, a zamrznute sveže plazme 2 
jedinice. Indikovanje transfuzija i eritrocita i trombocita bilo je adekvatno (91,85% 
bolesnika dobilo je transfuziju eritrocita pri Hb<70g/l, 89,2% primilo je transfuziju 
trombocita kad je broj trombocita bio niži od 20 x109/l). Tokom lečenja radio i 
hemiotrapijom došlo je do umanjenja hematoloških parametara, pri čemu su bolesnici 
eksperimentalne grupe bili zavisni od primene transfuzije krvi i nastavak njihove radio i 
hemioterapije bio je uslovljen primenom transfuzije eritrocita i trombocita. Statistički 
značajnije umanjenje koncentracije hemoglobina i broja trombocita registrovano je kod 
bolesnika koji su lečeni samo zračnom terapijom, te su oni ujedno i najveći potrošači 
produkata od krvi. Acta Medica Medianae 2008;47(4):13-18. 
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transfuzuijska terapija 